FDA
-
-
-
-
-
-
-
PTC Therapeutics Provides Regulatory Update on Translarna™
-
-
-
-
-
-
-
BofA Securities on Top Pick PTC Therapeutics (PTCT): 'We also see opportunity for upside within the pipeline'
-
-
-
-
-
-
-
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Citi Reiterates Neutral Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) to Sell Priority Review Voucher for $150M
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

